866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors

• Chang Liu,
• Manish Patel,
• Gerald Falchook,
• Patricia LoRusso,
• Timothy Yap,
• Melissa Johnson,
• Kristy Kuplast-Barr,
• Ryan Abo,
• Erika Manyak,
• Lisa Cleary,
• Viviana Bozon,
• Sudha Parasuraman,
• Heike Keilhack,
• Kristen McEachern

Affiliations

Chang Liu

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi`an, Shaanxi, China

Manish Patel

General Medicine, University Hospital Wishaw, Wishaw, UK

Gerald Falchook

Aff111 SCRI at HealthONE Denver CO USA

Patricia LoRusso

Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA

Timothy Yap

Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Kristy Kuplast-Barr

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Ryan Abo

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Erika Manyak

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Lisa Cleary

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Viviana Bozon

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Sudha Parasuraman

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Heike Keilhack

1Ribon Therapeutics, Inc, North Cambridge, MA, USA

Kristen McEachern

1Ribon Therapeutics, Inc, North Cambridge, MA, USA